ClinicalTrials.gov

ClinicalTrials.gov
Name	ClinicalTrials.gov
Founded	29 February 2000
Founder	National Institutes of Health (National Library of Medicine)
Location	Bethesda, Maryland
Key people	Deborah A. Zarin (former director)
Website	clinicaltrials.gov

ClinicalTrials.gov. It is a comprehensive registry and results database of publicly and privately supported clinical studies conducted around the world. Launched by the National Institutes of Health through its National Library of Medicine, it serves as a primary resource for patients, healthcare professionals, and researchers seeking information on the status and outcomes of medical research. The database is mandated by U.S. law and international guidelines to promote transparency and reduce publication bias in clinical research.

History and development

The registry was launched on February 29, 2000, following a mandate from the Food and Drug Administration Modernization Act of 1997. Its creation was driven by growing concerns over transparency and the need for a centralized repository for clinical trial information. A pivotal expansion occurred with the FDA Amendments Act of 2007, which introduced mandatory results reporting for certain trials. Key figures in its development include officials from the National Library of Medicine and advocates within the International Committee of Medical Journal Editors, which adopted a policy requiring trial registration as a condition for publication. Over time, its scope has broadened in response to policies from the World Health Organization and the International Clinical Trials Registry Platform.

Purpose and scope

The primary purpose is to provide a public database that enhances research transparency, informs patient enrollment, and helps fulfill ethical obligations to participants and society. It aims to combat selective reporting by making trial designs and outcomes publicly accessible. The scope encompasses interventional and observational studies across all diseases and conditions, conducted in over 200 countries. It includes trials sponsored by entities like the National Cancer Institute, Pfizer, and Mayo Clinic, covering phases from early Phase I studies to large Phase IV post-marketing surveillance.

Registration and reporting requirements

Legal requirements for registration and results submission are primarily enforced under U.S. law, including the FDA Amendments Act of 2007 and subsequent regulations from the Department of Health and Human Services. Generally, applicable clinical trials must register on the site before enrolling the first participant. Sponsors, such as Johnson & Johnson or academic centers like Harvard University, are required to submit detailed results information, including participant flow and outcome measures, within one year of trial completion. The Food and Drug Administration can impose penalties for non-compliance, including fines. Many journals, including The Lancet and The New England Journal of Medicine, also require registration for publication consideration.

Data structure and accessibility

The database uses a structured format with defined data elements, including descriptive information, recruitment status, eligibility criteria, and outcome measures. Key identifiers include the unique NCT number assigned to each record. The public interface, maintained by the National Library of Medicine, allows users to search and download data via a web portal or an API. Information is accessible to diverse users, from patients consulting the American Cancer Society to researchers at the European Medicines Agency. Data is available in XML format, facilitating its use in systematic reviews and meta-analyses conducted by organizations like the Cochrane Collaboration.

Impact and criticism

The registry has significantly increased clinical research transparency and has become an essential tool for Evidence-based medicine. It has enabled projects like the AllTrials campaign and analyses by the British Medical Journal to track reporting compliance. However, it has faced criticism for inconsistent data quality, incomplete results reporting, and challenges in ensuring timely updates from sponsors like GlaxoSmithKline. Studies have documented gaps in adherence to reporting mandates, prompting calls for stronger enforcement by the Food and Drug Administration. Comparisons with other registries, such as the European Union Clinical Trials Register, highlight ongoing challenges in achieving global harmonization.

Governance and funding

The operation and governance are managed by the National Library of Medicine within the National Institutes of Health, under the oversight of the U.S. Department of Health and Human Services. Key advisory input comes from groups like the Clinical Trials Transformation Initiative, a public-private partnership involving the Food and Drug Administration and Duke University. Primary funding is provided through the federal budget of the National Institutes of Health. International collaboration occurs through the World Health Organization’s registry network, and policy development often involves consultation with bodies like the Institute of Medicine (now the National Academy of Medicine).

Category:Medical research organizations Category:National Institutes of Health Category:Clinical research